Journals / Medicine Science / 2015 / Cilt: 4 - Sayı: 3

Comparison of Conventional Inflammatory Parameters with Tumor Necrosis Factor-α Levels in Different Stages of Diabetic Retinopathy and Non-Diabetic Controls

Pages
2364–2378
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Presence of a positive correlation between hsCRP and postprandial hyperglycemia indicates the importance of post absorptive glycemic excursions

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Aim of this study was to identify the risk factors associated with diabetic retinopathy in patients with Type 2 diabetes mellitus(DM), and to compare the levels of erythrocyte sedimentation rate (ESR), high sensitive CRP(hs-CRP) and tumor necrosis factor-α (TNF-α), in patients with every stage of diabetic retinopathy and non-diabetic healthy controls.
📊
Key Findings & Data:A total of 79 individuals, 64 diabetic and 25 healthy controls were included in the study.
💡
Conclusion & Impact:Presence of a positive correlation between hsCRP and postprandial hyperglycemia indicates the importance of post absorptive glycemic excursions
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Aim of this study was to identify the risk factors associated with diabetic retinopathy in patients with Type 2 diabetes mellitus(DM), and to compare the levels of erythrocyte sedimentation rate (ESR), high sensitive CRP(hs-CRP) and tumor necrosis factor-α (TNF-α), in patients with every stage of diabetic retinopathy and non-diabetic healthy controls. A total of 79 individuals, 64 diabetic and 25 healthy controls were included in the study. Patients were divided into three groups. Group 1 consisted of those without diabetic retinopathy (DR) (n=26), group 2 with non-proliferative (NPDR) (n=19), and group 3 with proliferative diabetic retinopathy (PDR) (n=19). Even though the similar age distribution, disease duration were different as 6.9 ± 6.5, 10.3 ± 5.4, and 12.7 ± 5.1 years in Group 1, Group 2 and Group 3, respectively (p>0.001). The majority of the patients with PDR were male, had high levels of albuminuria and high percents of receiving insulin treatment (p<0.05). The levels of ESR, hs-CRP and TNF-α were not different either in or between the groups. A positive correlation was observed between hs-CRP and postprandial blood glucose (p<0.001 and rho=0.621). Disease duration and metabolic control were considered as the most important determining factors with regard to the DR. Presence of a positive correlation between hsCRP and postprandial hyperglycemia indicates the importance of post absorptive glycemic excursions

🔖

Cite This Article

GÜÇLÜ, M., KADERLİ, B., ERSOY, C. (2015). Comparison of Conventional Inflammatory Parameters with Tumor Necrosis Factor-α Levels in Different Stages of Diabetic Retinopathy and Non-Diabetic Controls. Medicine Science, Cilt: 4 - Sayı: 3, 2364–2378. https://ajindex.com/articles/277755

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (17)

  1. Cumbie BC, Hermayer KL. Current concepts in targeted therapies for the pathophysiology of diabetic microvascular complications. Vasc Health Risk Manag. 2007;3(6):823-32
  2. Antonetti DA, Barber AJ, Bronson SK, Freeman WM, Gardner TW, Jefferson LS, Kester M, Kimball SR, Krady JK, LaNoue KF, Norbury CC, Quinn PG, Sandirasegarane L, Simpson IA; JDRF Diabetic Retinopathy Center Group. Diabetic retinopathy: seeing beyond glucose-induced microvascular disease. Diabetes. 2006;55(9):2401-11
  3. Fong DS, Aiello LP, Ferris FL 3rd, Klein R. Diabetic retinopathy. Diabetes Care. 2004;27(10):2540-53
  4. Mohamed Q, Gillies MC, Wong TY. Management of diabetic retinopathy: a systematic review. JAMA. 2007;298(8):902-16
  5. Aiello LM. Perspectives on diabetic retinopathy. Am J Ophthalmol. 2003;136(1):122- 35
  6. Cai J, Boulton M. The pathogenesis of diabetic retinopathy: old concepts and new questions. Eye. 2002;16:242-60
  7. Aiello LP, Cahill MT, Wong JS. Systemic considerations in the management of diabetic retinopathy. Am J Ophthalmol. 2001;16(3):242-60
  8. Szalai AJ. The biological functions of C-reactive protein Vascul Pharmacol. 2002;39(3):105-7
  9. Volanakis JE. Human C-reactive protein: expression, structure, and function. Mol Immunol. 2001;38(2-3):189-97
  10. Llorca J, González Quirós M, Sampedro I, García Unzueta MT, Berrazueta JR. Reproducibility of C-reactive protein analyses. Rev Esp Cardiol. 2002;55(10):1101-4
  11. Niessen HW, Hack CE. C-reactive protein and the risk of cardiovascular mortality. Am J Med. 2003;(3):241-2
  12. Tice JA, Browner W, Tracy RP, Cummings SR. The relation of C-reactive protein levels to total and cardiovascular mortality in older U.S. women. Am J Med. 2003;114(3):199-205
  13. Haffner SM. Pre-diabetes, insulin resistance, inflammation and CVD risk. Diabetes Res Clin Pract. 2003;61 Suppl 1:S9-S18
  14. Roberts WL, Sedrick R, Moulton L, Spencer A, Rifai N. Evaluation of four automated high-sensitivity C-reactive protein methods: implications for clinical and epidemiological applications. Clin Chem. 2000;46(4):461-8
  15. Festa A, D’Agostino R Jr, Howard G, Mykkänen L, Tracy RP, Haffner SM. Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS). Circulation. 2000;102(1):42-7
  16. Ford ES. Leukocyte count, erythrocyte sedimentation rate, and diabetes incidence in a national sample of US adults. Am J Epidemiol. 2002;155(1):57-64
  17. Ruan H, Lodish HF. Insulin resistan